Atyr PHARMA (ATYR) versus The Competition Critical Analysis

Atyr PHARMA (NASDAQ:ATYR) is one of 454 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Atyr PHARMA to similar businesses based on the strength of its risk, profitability, earnings, dividends, institutional ownership, valuation and analyst recommendations.

Volatility and Risk

Atyr PHARMA has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Comparatively, Atyr PHARMA’s rivals have a beta of 1.24, suggesting that their average share price is 24% more volatile than the S&P 500.

Profitability

This table compares Atyr PHARMA and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Atyr PHARMA	N/A	-56.92%	-43.87%
Atyr PHARMA Competitors	-11,413.86%	-123.30%	-24.18%

Institutional & Insider Ownership

61.7% of Atyr PHARMA shares are held by institutional investors. Comparatively, 31.8% of shares of all “Biotechnology” companies are held by institutional investors. 3.7% of Atyr PHARMA shares are held by insiders. Comparatively, 22.5% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for Atyr PHARMA and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atyr PHARMA	0	0	2	0	3.00
Atyr PHARMA Competitors	760	2460	5783	67	2.57

Atyr PHARMA currently has a consensus target price of $25.50, indicating a potential upside of 1,263.64%. As a group, “Biotechnology” companies have a potential upside of 17.37%. Given Atyr PHARMA’s stronger consensus rating and higher possible upside, equities analysts clearly believe Atyr PHARMA is more favorable than its rivals.

Earnings and Valuation

This table compares Atyr PHARMA and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Atyr PHARMA	$588,000.00	-$50.39 million	-2.08
Atyr PHARMA Competitors	$158.28 million	-$19.29 million	82.84

Atyr PHARMA’s rivals have higher revenue and earnings than Atyr PHARMA. Atyr PHARMA is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Atyr PHARMA beats its rivals on 7 of the 13 factors compared.

About Atyr PHARMA

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.